share_log

里昂:维持阿里健康(00241)“买入”评级 目标价降至4.1港元

Lyon: Maintaining Ali Health's (00241) “Buy” Rating Target Price Reduced to HK$4.1

Zhitong Finance ·  Apr 3 02:20

The Zhitong Finance App learned that Lyon released a research report stating that the target price for Ali Health (00241) was lowered from HK$5.6 to HK$4.1, maintaining the “buy” rating. The bank expects Alibaba Health to face a higher base effect than expected in the second half of fiscal year 2024. Revenue is expected to fall 19% year on year, and adjusted net profit is expected to drop 12% year on year. It also pointed out that Alibaba Health's business growth should be normalized in February of this year. Revenue and adjusted net profit for fiscal year 2025 are expected to increase by more than 16% and 70% respectively, benefiting from Ali Mama's advertising platform sharing advertising revenue.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment